SCHEMBL3520006

SCHEMBL3520006

CCOC(=O)CNC(=O)c1c(O)c(-c2cccc(F)c2)cc2ncc(Br)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 2/20 0.43
KDM4E B2RXH2 3/20 0.42
CSNK1D P48730 1/20 0.39
EGLN1 Q9GZT9 2/20 0.38
TRPM8 Q7Z2W7 1/20 0.38
MAOB P27338 1/20 0.37
HSD17B10 Q99714 2/20 0.37
PPID Q08752 1/20 0.37
RXFP1 Q9HBX9 1/20 0.36
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
PRNP P04156 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
DHODH Q02127 1/20 0.35
TOP2A P11388 1/20 0.35
JAK2 O60674 1/20 0.35
JAK3 P52333 1/20 0.35
VEGFA P15692 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3520873 0.81 EGLN3 (0.40) EGLN3KDM4ECSNK1DEGLN1TRPM8
SCHEMBL3524259 0.80 EGLN3 (0.52) EGLN3KDM4EHSD17B10PPIDALDH1A1
SCHEMBL3534707 0.80 EGLN3 (0.41) EGLN3KDM4ECSNK1DEGLN1TRPM8
SCHEMBL3517864 0.79 GPR35 (0.42) EGLN3KDM4ECSNK1DEGLN1RXFP1
SCHEMBL3758199 0.77 EGLN3 (0.39) EGLN3KDM4EEGLN1HSD17B10ALDH1A1
SCHEMBL3522299 0.77 EGLN3 (0.60) EGLN3EGLN1VEGFAFLT1
SCHEMBL3521029 0.77 EGLN3 (0.48) EGLN3KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL3760876 0.76 EGLN3 (0.54) EGLN3KDM4EEGLN1HSD17B10PPID
SCHEMBL3761475 0.76 NPC1 (0.45) EGLN3HSD17B10PPIDALDH1A1HPGD
SCHEMBL3521397 0.76 EGLN3 (0.46) EGLN3KDM4EHSD17B10ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885KDM4E 176/4885CSNK1D 2540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.